文献速递造血干细胞移植与细胞治疗

Unesbulin(PTC596)联合达卡巴嗪治疗局部复发、不可切除或转移性、复发或难治性平滑肌肉瘤的Ib期研究

Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma.
PubMed 文献 · J Clin Oncol · 2024-04-29

这项多中心、单臂、开放标签Ib期研究评估了unesbulin联合达卡巴嗪(DTIC)治疗晚期平滑肌肉瘤(LMS)的推荐II期剂量(RP2D)、安全性和初步疗效。确定unesbulin 300 mg每周口服两次联合DTIC 1,000 mg/m2每21天静脉给药一次为RP2D,在RP2D下可评估疗效的受试者客观缓解率为24.1%。

要点

  • unesbulin 300 mg每周口服两次联合DTIC 1,000 mg/m2每21天静脉给药一次被确定为RP2D。
  • 在27例可评估DLT的受试者中,400 mg组4例中3例(75%)发生DLT,200 mg组4例中1例(25%),300 mg组19例中3例(15.8%)。
  • 最常见DLT和治疗相关3-4级不良事件为血小板减少和中性粒细胞减少。

核心结论

  • unesbulin 300 mg每周两次联合DTIC 1,000 mg/m2每21天一次被确定为RP2D,在重度经治的晚期LMS成人患者中显示出有利的获益-风险特征。

研究设计与样本

  • 多中心、单臂、开放标签Ib期研究,纳入局部晚期、不可切除或转移性、复发或难治性LMS成人受试者。
  • unesbulin口服每周两次剂量递增联合DTIC 1,000 mg/m2静脉给药每21天一次,采用时间-事件持续重评估方法基于前两个21天治疗周期内评估的剂量限制性毒性(DLT)确定RP2D。
  • 所有探索的unesbulin剂量(200 mg至400 mg)均联合DTIC,并纳入扩展队列评估RP2D的安全性和疗效。

主要发现

  • 基于27例可评估DLT的受试者数据,unesbulin 400 mg组毒性更高,4例中3例(75%)发生DLT,而200 mg组4例中1例(25%)、300 mg组19例中3例(15.8%)发生DLT。
  • 最常见的DLT和治疗相关3级和4级不良事件为血小板减少和中性粒细胞减少。
  • 在RP2D下,7例可评估疗效的受试者达到部分缓解,客观缓解率为24.1%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This multicenter, single-arm, open-label, phase Ib study was designed to determine the recommended phase II dose (RP2D) and to evaluate the safety and preliminary efficacy of unesbulin plus dacarbazine (DTIC) in patients with advanced leiomyosarcoma (LMS). PATIENTS AND METHODS: Adult subjects with locally advanced, unresectable or metastatic, relapsed or refractory LMS were treated with escalating doses of unesbulin orally twice per week in combination with DTIC 1,000 mg/m2 intravenously (IV) once every 21 days. The time-to-event continual reassessment method was used to determine the RP2D on the basis of dose-limiting toxicities (DLTs) assessed during the first two 21-day treatment cycles. All explored doses of unesbulin (200 mg up to 400 mg) were in combination with DTIC. An expansion cohort was enrolled to evaluate the safety and efficacy of unesbulin at the RP2D. RESULTS: Unesbulin 300 mg administered orally twice per week in combination with DTIC 1,000 mg/m2 IV once every 21 days was identified as the RP2D. On the basis of data from 27 subjects who were deemed DLT-evaluable, toxicity was higher in the unesbulin 400 mg group, with three of four subjects (75%) experiencing DLTs versus one of four subjects (25%) in the 200 mg group and three of 19 subjects (15.8%) in the 300 mg group. The most commonly reported DLTs and treatment-related grade 3 and 4 adverse events were thrombocytopenia and neutropenia. At the RP2D, seven subjects who were efficacy evaluable achieved partial response for an objective response rate of 24.1%. CONCLUSION: Unesbulin 300 mg twice per week plus DTIC 1,000 mg/m2 once every 21 days was identified as the RP2D, demonstrating a favorable benefit-risk profile in a heavily pretreated population of adults with advanced LMS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Van Tine BA, Ingham MA, Attia S, et al. Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma. J Clin Oncol. 2024. PMID: 38684039. doi:10.1200/JCO.23.01684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。